Stockreport

89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024 [Yahoo! Fi...

89bio, Inc.  (ETNB) 
Last 89bio, inc. earnings: 3/18 04:05 pm Check Earnings Report
PDF SAN FRANCISCO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization [Read more]